Arthur D. Little Appoints Hiroto Suzuki as New Global Practice Leader for Automotive & Manufacturing
15.12.2020 12:00:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today announced that Hiroto Suzuki has been appointed as Global Leader for the Automotive & Manufacturing Practice. Suzuki will take over from Giancarlo Agresti, who has successfully led the practice for the last nine years, and was the driving force behind its increased global presence and diversification into different sub-industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005050/en/
Arthur D. Little appoints Hiroto Suzuki as new Global Practice Leader for Automotive & Manufacturing (Photo: Business Wire)
Based in ADL’s Tokyo office, Suzuki was previously responsible for relaunching ADL’s South-East Asia (SEA) operation, initiating a ‘Japan-Europe desk’, and working closely with China, the US and other markets. He has published several books on mobility and management topics, and is known as an opinion leader in the Japanese automotive and manufacturing industry.
Ignacio García Alves, Chairman and Chief Executive Officer of Arthur D. Little, comments: “I would like to express my personal gratitude to Giancarlo for the success he has brought to our Automotive & Manufacturing Practice, and congratulate Hiroto on taking up this key role within our company. His expertise in both automotive and mobility issues means that, as these sectors continue to converge, he is well qualified to help ADL establish leadership in this area. Hiroto’s experience of collaborating closely with both market leaders and other ADL practice heads will also be a major asset in progressing the company’s ambitions for the Automotive & Manufacturing Practice.”
Hiroto Suzuki, Practice Leader at Arthur D. Little, adds: “I am very pleased to be appointed to this exciting role. The global automotive industry is in the midst of a “once-in-a-century revolution” driven by disruptive mobile technologies, yet the manufacturing sector remains fragmented both industrially and geographically. However, I believe that there are many opportunities for convergence, and I am committed to developing these different domains while continuing to scale our business globally.”
After studying precision engineering at the University of Tokyo, Suzuki joined ADL in 2001, with his initial focus being the chemicals, electronics and heavy industries. He subsequently supported clients across a variety of segments, including suppliers, private equity, Japanese trading houses and government. More recently, he has focused on the automotive and mobility sectors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005050/en/
Contact information
Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 13:00:00 EEST | Press release
Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles the range and resolution of its lidar over the prior generation, adds native-color sensing, and is designed for functional safety. Based on patented Ouster Silicon with embedded Fujifilm color science, the L4 chip results in exquisite color data and hardware-enabled HDR. It boasts 42.9 GMACs of p
NIQ Research Reveals New Rules of Commerce: AI Is Beginning to Decide What Consumers Buy4.5.2026 13:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ) has announced the release of its new global report, The Commerce Revolution: Where East Meets West, which examines how Eastern-led commerce innovation and Western retail media monetization are colliding to reshape global consumer commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428841965/en/ The report finds live, social, and quick commerce—long scaled across Asia—now drive most incremental digital growth worldwide, while Western markets accelerate adoption as these formats localize. At the same time, retail media networks (RMNs) have become one of the fastest‑growing advertising channels globally, with US retail media ad spend projected to reach $107.6 billion (USD) in 2026. Beyond this, the report finds that previously siloed operational functions of sellers are beginning to blur boundaries. Payment platforms and rapid fulfillment models from the East are converging with the monetization mo
OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection4.5.2026 11:23:00 EEST | Press release
OPAQUE, the Confidential AI company headquartered in San Francisco, California, today announced it has acquired advanced cryptographic AI technologies from the Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi's Advanced Technology Research Council (ATRC). The acquired technology — already proven in real-world use cases — adds two critical capabilities to OPAQUE's platform: confidential AI model training powered by advanced cryptographic techniques such as multi-party computation and fully homomorphic encryption, as well as post-quantum cryptographic protections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504705475/en/ OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection (Photo: AETOSWire) Founded by researchers from UC Berkeley's RISELab, and now with this acquisition, OPAQUE supports Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom